NurExone Biologic (NRX.V) said Friday after trade it will hold a meeting on Sept. 15 for shareholders to vote on a proposal to consolidate its shares on the basis of up to 30 pre-consolidation shares for one post-consolidation share.
The company is evaluating a possible future listing on a major US stock exchange, and a higher post-consolidation trading price may improve NurExone's marketability, a statement said.
"The Board believes the proposed consolidation is a prudent enabling step in NurExone's broader capital markets strategy," said chair Yoram Drucker. "As the company continues to advance its novel biologic platform and pipeline, shareholder approval of the consolidation would provide the company with additional flexibility as it evaluates potential US capital markets alternatives and continues to pursue the next phase of its growth."
NurExone shares closed down C$0.08, or 11%, to C$0.62 on the TSX Venture Exchange.